+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Needle-Free Delivery Technology market set to grow to $2.7bn by 2022” says new Visiongain report

21 August 2018
Pharma

Visiongain’ has launched a new pharma report Needle-Free Delivery Technology Market  2018-2028: Jet Injector Technology, Competing Technologies, Novel Needle Technology, Inhaler Technology, Patch Technology.

The growth of the needle-free delivery technology is driven by unmet needs such as the high incidence of needlestick injuries and the need for a more efficient method of delivering mass vaccinations in rural areas. The market will also be boosted by biological drugs and the rapid growth in emerging market patient populations with access to novel medical devices.

In this report, needle-free drug delivery technologies encompass two types of injector technologies — jet injector technology and the competing needle-free technologies (novel needle technology, inhaler technology and transdermal patch technology). Novel needle technologies include both pen needles and microneedles.

The lead analyst of the report commented "It is anticipated that the future will see continued growth in biologics-drug delivery partnering deals. Visiongain predicts that manufacturers will look to novel self-administration devices as a key way to compete as the biosimilar market continues to rise over the next few years. Moreover, the diabetes biologic drug market represents a major driver for the needle-free delivery technology market."

Leading companies featured in the report include 3M, Antares Pharma, Becton Dickinson, BioJect Medical Technologies, PharmaJet, Zogenix.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read